SCPH RSI Chart
Last 7 days
3.6%
Last 30 days
-10.7%
Last 90 days
-5.3%
Trailing 12 Months
-57.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 0 | 0 | 0 | 13.6M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 18, 2024 | nokes rachael | acquired | - | - | 41,840 | cfo and treasurer |
Jan 18, 2024 | tucker john h | acquired | - | - | 113,560 | president and ceo |
Jan 02, 2024 | nokes rachael | sold (taxes) | -6,562 | 6.39 | -1,027 | cfo and treasurer |
Jan 02, 2024 | tucker john h | sold (taxes) | -31,579 | 6.39 | -4,942 | president and ceo |
Jan 19, 2023 | nokes rachael | acquired | 71,838 | 6.14 | 11,700 | see remarks |
Jan 19, 2023 | tucker john h | acquired | 409,323 | 6.14 | 66,665 | president and ceo |
Nov 25, 2022 | orbimed advisors llc | bought | 4,002,500 | 5.25 | 762,380 | - |
Oct 10, 2022 | 5am partners iv, llc | sold | -1,866,730 | 4.09 | -456,413 | - |
Oct 10, 2022 | 5am partners iv, llc | sold | -77,779 | 4.09 | -19,017 | - |
Oct 10, 2022 | 5am partners iv, llc | sold | -355,977 | 4.09 | -87,036 | - |
Which funds bought or sold SCPH recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 01, 2024 | Mirae Asset Global Investments Co., Ltd. | sold off | -100 | -93,323 | - | -% |
May 01, 2024 | BNP PARIBAS FINANCIAL MARKETS | added | 1.44 | -16,703 | 72,218 | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Apr 30, 2024 | Avior Wealth Management, LLC | new | - | 30.00 | 30.00 | -% |
Apr 29, 2024 | COMMONWEALTH EQUITY SERVICES, LLC | unchanged | - | -39,000 | 158,000 | -% |
Apr 25, 2024 | SIMPLEX TRADING, LLC | sold off | -100 | -20,000 | - | -% |
Apr 25, 2024 | Bank of New York Mellon Corp | reduced | -8.22 | -135,538 | 375,658 | -% |
Apr 24, 2024 | Assenagon Asset Management S.A. | new | - | 99,506 | 99,506 | -% |
Apr 23, 2024 | AMALGAMATED BANK | reduced | -76.19 | -21,000 | 5,000 | -% |
Apr 23, 2024 | RICE HALL JAMES & ASSOCIATES, LLC | added | 247 | 903,252 | 1,411,150 | 0.08% |
Unveiling Scpharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Scpharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 47.9B | 6.8B | -8.03 | 7 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.3B | 2.0B | -58.02 | 9.62 | ||||
BMRN | 15.7B | 2.5B | 76.24 | 6.34 | ||||
INCY | 12.1B | 3.8B | 16.19 | 3.2 | ||||
MID-CAP | ||||||||
APLS | 5.7B | 396.6M | -10.82 | 14.42 | ||||
BBIO | 5.2B | 107.9M | -9.53 | 48.09 | ||||
AXSM | 3.5B | 270.6M | -14.81 | 13.09 | ||||
ARWR | 3.0B | 240.7M | -10.2 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.79 | 3.86 | ||||
SMALL-CAP | ||||||||
CPRX | 1.7B | 398.2M | 24.31 | 4.36 | ||||
NVAX | 687.2M | 983.7M | -1.26 | 0.7 | ||||
CRBP | 408.0M | 881.7K | -9.15 | 466.16 | ||||
INO | 282.8M | 4.9M | -2.09 | 58.11 | ||||
IBIO | 6.9M | 2.1M | -0.25 | 2.14 |
Scpharmaceuticals Inc News
Income Statement (Quarterly) | |||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 |
Revenue | 60.6% | 6,096 | 3,796 | 1,638 | 2,063 |
Cost Of Revenue | 64.3% | 1,773 | 1,079 | 354 | 605 |
Operating Expenses | 14.6% | 21,353 | 18,635 | 15,384 | 13,617 |
S&GA Expenses | 14.9% | 16,242 | 14,135 | 12,096 | 10,896 |
R&D Expenses | -2.4% | 3,338 | 3,421 | 2,934 | 2,116 |
Interest Expenses | 1.6% | 2,092 | 2,060 | 2,010 | 1,961 |
Net Income | 11.7% | -13,812 | -15,634 | -14,154 | -11,210 |
Net Income Margin | -Infinity% | -4.03* | - | - | - |
Free Cashflow | -12.6% | -15,151 | -13,451 | -14,141 | -16,494 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -11.0% | 94.00 | 106 | 114 | 127 | 124 | 48.00 | 59.00 | 69.00 | 79.00 | 88.00 | 94.00 | 100 | 109 | 117 | 124 | 80.00 | 77.00 | 87.00 | 83.00 | 88.00 | 94.00 |
Current Assets | -10.9% | 93.00 | 104 | 114 | 127 | 123 | 47.00 | 58.00 | 68.00 | 78.00 | 86.00 | 92.00 | 99.00 | 108 | 116 | 123 | 79.00 | 76.00 | 85.00 | 82.00 | 86.00 | 92.00 |
Cash Equivalents | 33.6% | 47.00 | 35.00 | 71.00 | 75.00 | 71.00 | 41.00 | 41.00 | 52.00 | 74.00 | 80.00 | 75.00 | 76.00 | 72.00 | 44.00 | 79.00 | 76.00 | 73.00 | 84.00 | 80.00 | 84.00 | 90.00 |
Inventory | 24.1% | 9.00 | 7.00 | 6.00 | 4.00 | 1.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | 48.7% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 0.5% | 57.00 | 57.00 | 51.00 | 52.00 | 52.00 | 17.00 | 19.00 | 20.00 | 23.00 | 24.00 | 25.00 | 25.00 | 27.00 | 27.00 | 26.00 | 25.00 | 26.00 | 29.00 | 20.00 | 17.00 | 15.00 |
Current Liabilities | 19.9% | 13.00 | 11.00 | 7.00 | 8.00 | 7.00 | 17.00 | 16.00 | 14.00 | 15.00 | 14.00 | 12.00 | 10.00 | 9.00 | 7.00 | 6.00 | 5.00 | 5.00 | 8.00 | 14.00 | 10.00 | 7.00 |
Long Term Debt | 1.4% | 39.00 | 38.00 | 38.00 | 37.00 | 37.00 | - | 2.00 | 5.00 | 7.00 | 10.00 | 12.00 | 15.00 | 17.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 5.00 | 6.00 | 7.00 |
LT Debt, Current | - | - | - | - | - | - | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 7.00 | 5.00 | 2.00 | - | - | - | - | - | 5.00 | 4.00 | 3.00 |
LT Debt, Non Current | 1.4% | 39.00 | 38.00 | 38.00 | 37.00 | 37.00 | - | 2.00 | 5.00 | 7.00 | 10.00 | 12.00 | 15.00 | 17.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 5.00 | 6.00 | 7.00 |
Shareholder's Equity | -24.3% | 37.00 | 49.00 | 63.00 | 76.00 | 72.00 | 31.00 | 40.00 | 49.00 | 56.00 | 63.00 | 69.00 | 76.00 | 82.00 | 90.00 | 98.00 | 55.00 | 51.00 | 58.00 | 63.00 | 70.00 | 79.00 |
Retained Earnings | -5.2% | -281 | -267 | -251 | -237 | -226 | -217 | -207 | -197 | -189 | -182 | -175 | -168 | -161 | -153 | -144 | -136 | -129 | -118 | -112 | -105 | -96.46 |
Additional Paid-In Capital | 0.6% | 319 | 317 | 315 | 314 | 299 | 248 | 248 | 247 | 246 | 245 | 245 | 244 | 244 | 244 | 243 | 192 | 181 | 177 | 176 | 176 | 175 |
Shares Outstanding | 0.3% | 36.00 | 36.00 | 36.00 | 36.00 | 34.00 | 27.00 | 27.00 | 27.00 | 27.00 | 27.00 | 27.00 | 27.00 | 27.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | 274 | - | - | - | 76.00 | - | - | - | 94.00 | - | - | - | 113 | - | - | - | 27.00 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -12.4% | -15,114 | -13,451 | -14,141 | -16,494 | -11,837 | -8,196 | -7,175 | -7,369 | -7,098 | -5,167 | -6,271 | -8,615 | -9,180 | -4,808 | -5,962 | -7,743 | -14,835 | -5,578 | -3,911 | -6,118 | -5,801 |
Share Based Compensation | 10.5% | 1,416 | 1,281 | 1,179 | 980 | 737 | 785 | 680 | 636 | 637 | 619 | 589 | 521 | 127 | 744 | 621 | 508 | 435 | 333 | 326 | 355 | 453 |
Cashflow From Investing | 215.4% | 26,463 | -22,925 | 9,427 | 7,000 | -42,992 | 10,784 | -861 | -12,790 | 4,501 | 9,521 | 5,403 | 12,705 | 36,701 | -29,692 | - | - | - | - | - | - | - |
Cashflow From Financing | 586.8% | 467 | 68.00 | 611 | 13,704 | 84,601 | -2,477 | -2,416 | -2,479 | -2,458 | - | - | -72.00 | 20.00 | -82.00 | 49,952 | 10,458 | 3,897 | 9,673 | - | 18.00 | -61.00 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||
Product revenues, net | $ 13,593 | |
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] | us-gaap:ProductMember | |
Operating expenses: | ||
Cost of product revenues | $ 3,811 | |
Research and development | 11,809 | $ 15,533 |
Selling, general and administrative | 53,369 | 20,624 |
Total operating expenses | 68,989 | 36,157 |
Loss from operations | (55,396) | (36,157) |
Other income | 3,605 | 1,418 |
Interest income | 5,104 | 1,203 |
Interest expense | (8,123) | (3,302) |
Net loss | $ (54,810) | $ (36,838) |
Net loss per share, basic | $ (1.42) | $ (1.3) |
Net loss per share, diluted | $ (1.42) | $ (1.3) |
Weighted --average common shares outstanding, basic | 38,513,747 | 28,358,502 |
Weighted--average common shares outstanding, diluted | 38,513,747 | 28,358,502 |
Other comprehensive loss: | ||
Unrealized gain (loss) on short-term investments | $ (33) | $ 33 |
Comprehensive loss | $ (54,843) | $ (36,805) |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 46,814 | $ 71,061 |
Short-term investments | 29,199 | 47,125 |
Restricted cash | 182 | |
Accounts receivable | 4,489 | |
Inventory | 8,840 | 1,230 |
Prepaid expenses | 2,436 | 2,282 |
Deposits and other current assets | 1,160 | 1,428 |
Total current assets | 92,938 | 123,308 |
Property and equipment, net | 58 | 54 |
Right-of-use lease assets - operating, net | 1,401 | 566 |
Deposits and other assets | 82 | 267 |
Total assets | 94,479 | 124,195 |
Current liabilities | ||
Accounts payable | 4,001 | 1,518 |
Accrued expenses | 8,901 | 5,289 |
Lease obligation - operating, short-term | 176 | 567 |
Other current liabilities | 56 | 42 |
Total current liabilities | 13,134 | 7,416 |
Term loan, long-term | 38,811 | 36,794 |
Derivative liability | 3,857 | 7,517 |
Lease obligation - operating, long-term | 1,282 | 7 |
Other liabilities | 177 | 28 |
Total liabilities | 57,261 | 51,762 |
Commitments and contingencies (Note 13) | ||
Stockholders’ Equity | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding | ||
Common stock; $0.0001 par value; 150,000,000 shares authorized at December 31, 2023; 34,257,916 and 35,968,510 shares issued and outstanding at December 31, 2022 and December 31, 2023, respectively | 4 | 3 |
Additional paid-in capital | 318,561 | 298,934 |
Accumulated deficit | (281,346) | (226,536) |
Accumulated other comprehensive (loss) income | (1) | 32 |
Total stockholders’ equity | 37,218 | 72,433 |
Total liabilities and stockholders’ equity | $ 94,479 | $ 124,195 |